Bristol Myers Squibb stock at USD 63.88 on September 28, 2026
📈 BMY stock closed at USD 63.88 on September 28, 2026, up 1.62% from the prior session.
🔬 Bristol Myers Squibb announced Phase 3 EXCALIBER-RRMM trial results for ZENBEXUS in multiple myeloma.
📊 The ZENBEXUS combination achieved a 41.10% minimal residual disease-negative complete response rate versus 20.70% for the comparator.
📅 Trial data was presented at the 2026 International Myeloma Society meeting and published in The Lancet Oncology.
💰 The company declared a quarterly dividend of USD 0.63 per share payable on November 2, 2026.
Bullish Signals
- Bristol Myers Squibb reported positive Phase 3 data for ZENBEXUS in multiple myeloma, showing a 41.10% complete response rate versus 20.70% for the comparator.
- The company's stock price increased by 1.62% to close at USD 63.88 following the announcement of clinical trial results.
Full Analysis
Bristol Myers Squibb (BMY) shares closed at USD 63.88 on September 28, 2026, representing a gain of USD 1.02 or 1.62% from the previous session's close of USD 62.86. The stock traded on the New York Stock Exchange as of 20:00:02 UTC.
On September 25, 2026, the company announced positive Phase 3 trial results for its multiple myeloma candidate ZENBEXUS (iberdomide) in combination with daratumumab and dexamethasone. The EXCALIBER-RRMM trial evaluated the treatment in 420 patients with relapsed or refractory disease.
The study demonstrated a minimal residual disease-negative complete response rate of 41.10% for the ZENBEXUS combination, compared to 20.70% for the comparator regimen of daratumumab, bortezomib, and dexamethasone. These results were presented at the 2026 International Myeloma Society meeting and published in The Lancet Oncology.
Additionally, Bristol Myers Squibb's board declared a quarterly dividend of USD 0.63 per share on September 16, 2026. This dividend is scheduled to be payable on November 2, 2026, to shareholders of record as of October 2, 2026.
